Attovia Therapeutics, Inc. — Form SCHEDULE 13D
Filed August 11, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 22/100
What the filing says
Three Frazier Life Sciences funds (Public Fund L.P., XI L.P., and XII L.P.) filed a joint Schedule 13D on August 11, 2026, indicating they have crossed a 5% beneficial ownership threshold in Attovia Therapeutics common stock. The filing itself contains only the joint filing agreement; specific share counts, dollar amounts, and ownership percentages are not disclosed in this exhibit.
Why this rating
Schedule 13D filing is routine disclosure requirement when ownership crosses 5%. No deal, financing, or operational change announced. Frazier is known healthcare investor. Awaiting full Schedule 13D for material details.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.